- Home
- LOCO vs AVIR Comparison
LOCO vs AVIR Comparison
Compare LOCO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- AVIR
- Stock Information
- Founded
- LOCO 1980
- AVIR 2012
- Country
- LOCO United States
- AVIR United States
- Employees
- LOCO N/A
- AVIR N/A
- Industry
- LOCO Restaurants
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- LOCO Consumer Discretionary
- AVIR Health Care
- Exchange
- LOCO Nasdaq
- AVIR Nasdaq
- Market Cap
- LOCO 270.6M
- AVIR 275.6M
- IPO Year
- LOCO 2014
- AVIR 2020
- Fundamental
- Price
- LOCO $11.20
- AVIR $3.25
- Analyst Decision
- LOCO Buy
- AVIR Hold
- Analyst Count
- LOCO 3
- AVIR 1
- Target Price
- LOCO $15.50
- AVIR $6.00
- AVG Volume (30 Days)
- LOCO 397.2K
- AVIR 402.4K
- Earning Date
- LOCO 07-31-2025
- AVIR 08-06-2025
- Dividend Yield
- LOCO N/A
- AVIR N/A
- EPS Growth
- LOCO 6.54
- AVIR N/A
- EPS
- LOCO 0.86
- AVIR N/A
- Revenue
- LOCO $476,032,000.00
- AVIR N/A
- Revenue This Year
- LOCO $6.28
- AVIR N/A
- Revenue Next Year
- LOCO $1.14
- AVIR N/A
- P/E Ratio
- LOCO $13.05
- AVIR N/A
- Revenue Growth
- LOCO 1.22
- AVIR N/A
- 52 Week Low
- LOCO $8.29
- AVIR $2.46
- 52 Week High
- LOCO $14.25
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- LOCO 66.21
- AVIR 63.83
- Support Level
- LOCO $10.17
- AVIR $3.15
- Resistance Level
- LOCO $11.01
- AVIR $3.35
- Average True Range (ATR)
- LOCO 0.38
- AVIR 0.13
- MACD
- LOCO -0.01
- AVIR 0.00
- Stochastic Oscillator
- LOCO 88.14
- AVIR 73.24
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).